DP
IRWD icon

Diadema Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Diadema Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-683,611
Closed -$2.3M – 173
2025
Q4 		$2.3M Buy
+683,611
New +$1.78M 0.4% 55

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Diadema Partners's IRWD Position: Q1 2026 in Review

Diadema Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 683,611 shares — an estimated $2.3M sold.

Diadema Partners first reported a position in IRWD in Q4 2025 and held it in 1 quarter. The position peaked at $2.3M in Q4 2025. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Diadema Partners reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 683,611 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $2.3M.
  • Diadema Partners first reported a position in Ironwood Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Diadema Partners's Ironwood Pharmaceuticals position peaked at $2.3M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.